In this study, we have characterized functional EP receptors in human corpus cavernosum (HCC) tissue and in HCC smooth muscle cells (SMC). Using RNase protection assays, we determined expression of EP2, EP3 I and EP3 II receptor mRNA. In organ bath preparations of HCC tissue strips, PGE 1 caused dose-dependent relaxation at concentrations below 300 nM. At concentrations greater than 300 nM, PGE 1 caused contraction. Addition of the EP1/EP2/EP3 receptor antagonist AH6809 inhibited this contraction and facilitated further relaxation through concentrations above 1 lM of PGE 1 . The EP1/EP3 receptor selective agonist 17-phenyltrinor-PGE 2 caused dose-dependent contraction that was partially attenuated by SC51322, an EP1 selective antagonist. In cultures of HCC SMC, PGE 1 stimulated cAMP accumulation in a dose-dependent manner. Interestingly, AH6809 significantly attenuated PGE 1 -induced cAMP accumulation. Sulprostone, a selective EP3 receptor agonist, induced weak contractions in HCC tissue strips but augmented forskolin-induced cAMP synthesis in HCC SMC. The data in this study suggest that HCC and cultured smooth muscle cells express EP1, EP2 and EP3 receptors. These receptors mediate their responses via different biochemical pathways and are expected to have different responses in regulating smooth muscle tone. Thus, we suggest that the ultimate response in erectile tissue to various prostanoids is the integration of responses elicited by individual EP receptor subtypes to a given ligand.
Introduction
Eicosanoids are synthesized from 20 carbon unsaturated fatty acids (the most common being arachidonic acid) and are local acting autacoids that mediate a variety of effects including smooth muscle relaxation and contraction. [1] [2] [3] These substances, which include prostaglandin E (PGE), mediate their effects on smooth muscle by interaction with specific G-protein coupled receptors. The corpus cavernosum synthesizes prostacyclin (PGI 2 ), PGE 2 , PGF 2a and thromboxane A 2 . 4, 5 In addition, corpus cavernosum smooth muscle cells (SMC) in culture have been shown to synthesize PGD 2 , PGE 2 and PGF 2a , all of which are regulated by oxygen tension. 6 Of these eicosanoids, only PGE 1 has been reported to relax penile cavernosal smooth muscle. [7] [8] [9] [10] Further, arachidonic acid, the precursor of PGE 2 , can relax human corpus cavernosum (HCC) smooth muscle in the presence of thromboxane receptor antagonists, a process blocked by the prostaglandin G/H synthase inhibitor indomethacin. 10 Prostaglandin E can bind to several different subtypes of EP receptors. EP1 (Ga q11 -coupled) and EP3 (Ga i/ocoupled) receptors can potentially mediate trabecular smooth muscle contraction, while EP2 and EP4 (Ga s -coupled) may mediate trabecular smooth muscle relaxation via different signal transduction pathways. [1] [2] [3] Furthermore, the EP3 receptor can exist as six different splice variants. 3 In the light of the current use of injectable and intraurethral PGE 1 to treat erectile dysfunction and since PGE 1 has the potential to bind to nine distinct EP receptor subtypes, an understanding of the prostaglandin receptors in corpus cavernosum is critical for designing and targeting effective therapy.
The lack of specific receptor antagonists and limited selective agonists suggests that characterization of EP receptors may require a combination of molecular biologic and pharmacologic approaches. The advances over the past decade in molecular biology paved the way for investigation of the expression and function of these receptors, especially in the light of cDNA cloning and genomic mapping of the specific receptors for PGD, PGE, PGF 2a , PGI and TxA 2 .
1-3 The presence of EP1 receptors in the penis and a potential role for this receptor in the pain associated with PGE 1 injection has been proposed.
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EP1 receptors are G q/11 coupled and would be expected to contract corpus cavernosum tissue. The availability of selective tools to distinguish pharmacologically individual EP receptor families is limited. In this report, we investigated the expression and function of EP1, EP2 and EP3 receptors in HCC tissue and in HCC SMC. . The RNA to be tested was precipitated in the presence of 0.5 M ammonium acetate (30-40 mg for HCC biopsies and 30-40 mg for HCC SMC cultures), dried and used immediately for the assay. The hybridizations were carried out for 18-h at 451C. RNase digestions after hybridization were allowed to proceed for 90 min at 371C. After inactivation of RNase and precipitation of the protected fragments, samples were electrophoresed on 40 cm 5% urea-polyacrylamide denaturing gels, dried and subjected to autoradiography.
Methods

Chemicals and supplies
Assay of cAMP in tissue culture cells
HCC SMC were prepared as previously reported. 12 Cells were grown to confluence in DMEM containing 25 U/ml penicillin, 250 U/ml streptomycin, 25 U/ml nystatin, 2 mM glutamine and supplemented with 10% fetal bovine serum. The cells were refed with the same media 24 h before the experiment. Cells were then treated with either 10 mM PGE 1 , 10 mM PGE 1 plus 10 mM AH6809 or 10 mM forskolin with varying concentrations of sulprostone. All treatments were for 5 min. Assays for cAMP were carried out as previously described. 13 
Organ baths
Organ bath experiments were carried out as previously reported. 9 Strips of HCC were mounted to tension transducers and submerged in thermostated (371C) 25 ml organ baths containing bicarbonate buffered physiologic salt solution (PSS; 118.3 mM NaCl, 4.7 mM KCl, 0.6 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 , 25 mM NaHCO 3 , 0.026 mM CaNa 2 ED-TA, 11.1 mM glucose) and aerated with 95% air/5% CO 2 to attain a pH of 7.4. Optimal isometric tension for contraction was attained as described previously. 9 All experiments were carried out in the presence of 3 mM indomethacin to inhibit production of endogenous arachidonic acid metabolites. Dose-responses to 17-PTP, PGE 1 and sulprostone were carried out by cumulative addition. In some experiments, tissue strips were incubated for 20-30 min with 10 mM bretylium before beginning the dose-response. Relaxation responses were normalized as percent of tone caused by 1 mM phenylephrine. Contractile responses were normalized as percent of tone caused by PSS containing 80 mM K + . Baseline tension was determined at the end of each experiment by exposing tissue strips to 10 mM papaverine and 10 mM nitroprusside. The selectivity of the various EP agonists/antagonists used in these experiments is shown in Table 2 .
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Results
Expression of EP2 and EP3 receptor mRNA in HCC
The EP2 receptor mRNA was detected as a 398 bp protected fragment expressed in both HCC and in cultured HCC SMC (Figure 1a ). In addition, mRNA for EP3 I and EP3 II receptors was detected as 549 and 446 bp protected fragments, respectively (Figure 1b and c). Of these two different receptor variants, EP3 II is the most interesting as it has been shown to couple to Ga s , increasing cAMP synthesis (EP3 receptors normally couple through Ga i , decreasing cAMP synthesis). 2 The other bands at lower molecular weights on the EP3 RPA gels suggest the presence of other splice variants present in corpus cavernosum tissue and cells. Of the receptor mRNAs examined, the EP2 receptor (Figure 1a ) appeared the most abundant based on exposure time using equal amounts of total RNA, and was apparent in HCC smooth muscle biopsies as well as in cultured cells. We have previously demonstrated the expression of EP2 and EP4 receptors in HCC and in cultured SMC using RT-PCR. 6 We were not successful in demonstrating EP1 receptor mRNA expression either by RNase protection or RT-PCR (data not shown) despite pharmacologic functional evidence suggesting the presence of these receptors (see below).
Effects of EP agonists in HCC
We utilized the EP1/EP3 selective agonist 17-PTP-PGE 2 (see Table 2 ) in combination with the EP1 selective antagonist SC51322 to demonstrate functional EP1 receptors in HCC smooth muscle. The agonist 17-PTP induced potent contractions in trabecular smooth muscle strips in organ baths (EC 50 B100 nM, Figure 2a) . To further confirm the presence of pharmacologic EP1 receptors, the effects of the EP1 antagonist SC51322 on 17-PTP contractions were examined. This antagonist attenuated the contractile response to 17-PTP at concentrations below 30 mM, as indicated by the shift of the doseresponse curve to the right (Figure 2a) . Interestingly, at concentrations above 30 mM 17-PTP, EP1 blockade by SC51322 potentiated contraction. It has been reported that EP1/EP3 agonists can either stimulate or inhibit release of norepinephrine from nerve terminals through prejunctional receptors. 18, 19 To determine if the contraction to 17-PTP was due in part to norepinephrine release, we used the sympathetic nerve inhibitor bretylium. Interestingly, bretylium potentiated rather than inhibited the actions of 17-PTP (Figure 2b) .
In HCC tissue strips contracted with phenylephrine, PGE 1 caused smooth muscle relaxation (EC 50 B20 nM). At concentrations greater than 1 mM, PGE 1 induces contraction (Figure 4a ), which is attributed to cross-reactivity with TP (thromboxane A 2 ) receptors since the TP receptor antagonist SQ29548 blocks this contraction. 9, 10 Since PGE 1 binds to all four EP receptor subtypes, we examined the contribution of EP1, EP2 and EP3 receptor subtypes with the antagonist AH6809 ( Table 2 ). Treatment (Figure 3a) . However, AH6809 attenuated cAMP accumulation in HCC SMC and shifted the doseresponse curve to the right (EC 50 B200 nM to 2 mM; Figure 3b ). The role of EP3 receptors in regulating smooth muscle contractility was examined using the EP3 selective agonist sulprostone. Sulprostone induced very weak contractions in HCC, with significant effects only at the highest concentrations (Figure 4a) . In HCC SMC, the effects of sulprostone on forskolininduced cAMP synthesis were examined. Since EP3 receptors are Ga i/o coupled, one would expect an inhibition of cAMP synthesis similar to what has been reported for the a 2 -adrenergic receptor. 20 However, no inhibition was noted (Figure 4b ) and at the higher concentrations of sulprostone, a stimulation of cAMP synthesis was observed, consistent with coupling to Ga s as has been reported for muscarinic receptors HCC SMC. Functional EP receptors in human corpus cavernosum RB Moreland et al Discussion PGE 1 has been used to diagnose and treat erectile dysfunction for almost 20 y. 8, 22, 23 However, the exact mechanisms by which PGE 1 relaxes smooth muscle and which receptors are present on HCC smooth muscle remain to be elucidated. The pharmacology of PGE 1 is complicated by the presence of multiple G-protein-coupled receptors, which signal through varying pathways. EP2 and EP4 receptors are thought to be involved in mediating smooth muscle relaxation, whereas EP1 and EP3 may be involved in smooth muscle contraction. The EP1 receptor subtype has been implicated in pain and allodynia, which may be attenuated by nitric oxide. [24] [25] [26] [27] This is of special interest since one of the major complaints with intracavernosal PGE 1 is pain. 8 In organ bath studies, PGE 1 produces dose-dependent relaxation in HCC tissue strips, and at higher concentrations, crossreacts with thromboxane A 2 (TP) receptors, producing contraction. 9, 10 In this report, we have demonstrated expression of mRNA for EP2, EP3 I and EP3 II receptors as well as functional demonstration of EP1, EP2 and EP3 receptors. The EP1/EP3 selective agonist 17-PTP caused dose-dependent contraction in HCC tissue. The EP1 selective antagonist SC51322 inhibited contraction to 17-PTP in HCC tissue strips at concentrations below 3 mM and enhanced contraction at concentrations greater than 3 mM. While the inhibition of 17-PTP-induced contraction suggests the presence of functional EP1 receptors on HCC smooth muscle, the potentiation at higher concentrations suggests the involvement of other regulatory mechanisms. EP1/EP3 agonists have previously been shown to either stimulate or inhibit release of norepinephrine from nerve terminals. 18, 19 However, in mammalian tissues, prejunctional EP3 receptors inhibit norepinephrine release. 18 This inhibitory action of prejunctional EP3 receptors is consistent with our data. Assuming that there is basal release of norepinephrine in isolated cavernosal tissue strips, it is possible that higher concentrations of 17-PTP bind to prejunctional EP3 receptors and inhibit basal release of norepinephrine. In the presence of 10 mM SC51322, there may be partial blockade of EP3 receptors in addition to antagonism of EP1, facilitating basal norepinephrine release. This could result in a slightly enhanced contractile response despite the antagonism of EP1/EP3 receptors on the trabecular smooth muscle.
To further examine potential regulation of the EP1/EP3-mediated contractile response by sympathetic nerves, we carried out dose responses to 17-PTP in the presence of bretylium to inhibit norepinephrine release. Interestingly, we observed that bretylium potentiated contraction to 17-PTP. Bretylium is known to inhibit norepinephrine reuptake and consequently increase synaptic concentrations of the neurotransmitter in a transient manner. However, it is unlikely that this mechanism is responsible for the large enhancement in 17-PTPinduced contraction since all tissue strips were incubated with bretylium for 20-30 min before beginning the dose response. We have previously demonstrated that this time period is sufficient to inhibit neurogenic contraction completely in cavernosal tissue strips. 28 Alternatively, bretylium, a quaternary ammonium compound, has been shown to block K + channels and inhibit hyperpolarization and relaxation of various smooth muscle tissues. 29, 30 Although the specific receptor subtypes have not been identified, PGE 1 has been shown to activate the large-conductance K Ca channels in penile cavernosal tissue via a protein kinase A-mediated mechanism. 31 Thus, bretylium may block K + channel-mediated hyperpolarization to enhance contraction substantially to 17-PTP. However, this would suggest that 17-PTP, in part, stimulates cAMP production. The EP3 receptor is the most diverse of the four subtypes of PGE receptors. There are six different alternatively spliced isoforms differing in the third intracellular loop after the seventh transmembrane domain.
1-3 As a result, most EP3 isoforms are coupled to Ga i/o and inhibit cAMP. However, the EP3 II isoform (EP3D) can also couple to Ga s and can increase cAMP. 2, 12, 33 Thus, it is possible that 17-PTP may stimulate EP3 II receptors to increase cAMP.
Further evidence for the complex nature of EP3 receptors can be seen in the functional responses to the EP3 agonist sulprostone. While sulprostone at high concentrations (1 mM) caused weak contraction in isolated HCC tissue strips, it actually enhanced forskolin-induced cAMP accumulation at identical Figure 4 Effects of EP3 agonist sulprostone on HCC tissue strips and HCC SMC. Organ bath preparations of human cavernosal tissue strips at optimal isometric tension were contracted with physiological salt solution containing 80 mM K + . After washout, tissues were subjected to cumulative additions of sulprostone. Data are expressed as percent of contraction to physiological salt solution containing 80 mM K + (panel a; n ¼ 6). Primary cultures of human cavernosal SMC were incubated with 10 mM forskolin and increasing concentrations of sulprostone for 5 min and cAMP was measured by radioimmunoassay in deproteinized cell extracts (panel b; data represent cells from three different patients).
Functional EP receptors in human corpus cavernosum RB Moreland et al concentrations. Thus, cAMP accumulation does not necessarily predict the tonic response. A dissociation between relaxation and cAMP accumulation may also be seen with AH6809, a nonselective antagonist for EP1, EP2 and EP3 receptors. AH6809 potentiated PGE 1 -induced relaxation of HCC tissue but reduced PGE 1 -induced cAMP synthesis in cultured SMC. Since this agent has significantly lower affinity for EP4 receptors (Table 2) , it is likely that the enhanced relaxation is due to inhibition of EP1 and EP3 I receptors, while the attenuation in cAMP synthesis is due to inhibition of EP2 and EP3 II receptors. We have previously shown that AH6809 inhibited PGE1-induced cAMP synthesis in cultured SMC at high oxygen tension. 6 In addition, the EP2 selective agonist butaprost effectively relaxed HCC smooth muscle strips in organ baths. 10 These observations confirm that EP2 receptors are involved in HCC relaxation while EP1 and EP3 I receptors may mediate contraction.
In summary, we have demonstrated the expression of EP2, EP3 I and EP3 II receptors at the mRNA level and EP1, EP2 and EP3 receptors by functional studies. These data together with our previous work suggest that HCC expresses all four known subtypes of EP receptors. 6 We suggest that EP2, EP3 II and EP4 receptors predominate in mediating smooth muscle relaxation and EP1 and EP3 I receptors modulate contraction. It remains to be determined what role these receptors may play in the physiology and pathophysiology of erectile function. The availability of receptor knockout mice as well as the reports of selective agonists and antagonists for these receptor subtypes should enable further investigation of the pharmacology of EP receptors as well as potential development of improved therapeutics for erectile dysfunction. 32, 33 
